Axatilimab-csfr (Niktimvo)
Dilution requiredFull monograph review pending
U.S. label preparation
Niktimvo · Dilution required
- Preparation
- Check the vial strength and stock concentration before drawing up drug. Use 0.9% sodium chloride for a final concentration of 0.24-0.75 mg/mL.
- Administration and handling
- Different presentations contain different amounts per mL. Follow the prescribed dose and the matching vial in the preparation table.
Product and source details
Incyte Corporation · BLA761411
Product NDC: 50881-034, 50881-023, 50881-036, 50881-047
SPL effective 2026-09-25 | SPL version 9. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.